Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa Bay news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Charlotte news in your inbox

Catch up on the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Russia’s vaccine gamble

Russia announced Tuesday that it approved a vaccine for COVID-19 and has plans to inoculate health care workers, teachers and others in the coming months, despite barely starting Phase 3 clinical trials.

Axios Re:Cap digs into the ramifications of this announcement for the global vaccine race with Derek Lowe, medicinal chemist, author and expert on drug development and the pharmaceutical industry.

Go deeper

Oriana Gonzalez
Nov 18, 2020 - Health

Pfizer says latest data shows its coronavirus vaccine is safe and 95% effective

Photo: Dogukan Keskinkilic/Anadolu Agency via Getty Images

Pfizer said on Wednesday that its coronavirus vaccine is 95% effective and has no serious side effects.

The state of play: The company said they have enough safety data now and plan to request an emergency use authorization from the Food and Drug Administration "within days."

Go deeper (1 min. read)Arrow
Axios
Updated 42 mins ago - Politics & Policy

Coronavirus dashboard

Illustration: Eniola Odetunde/Axios

  1. Health: Communities of color are falling behind in America's vaccine effort.
  2. Politics: Hundreds of Biden staffers receive COVID vaccine — Axios-Ipsos poll: Trust in federal COVID-19 response surges.
  3. Business: Bankruptcy filings hit decade-high last year.
  4. World: U.K. surpasses 100,000 COVID-19 deaths — 44% of Israelis have already received at least one vaccine dose.
  5. Sports: Pandemic has cost the NCAA $600 million — CDC looks at lessons learned from NFL's testing and contact tracing.
Go deeper (1 min. read)Arrow
Dave Lawler, author of World
56 mins ago - World

Biden holds first phone call with Putin, raises Navalny arrest

Putin takes a call in 2017. Photo: Handout/Anadolu Agency/Getty

President Biden on Tuesday held his first call since taking office with Vladimir Putin, pressing the Russian president on the arrest of opposition leader Alexey Navalny and the Russia-linked hack on U.S. government agencies, AP reports.

The state of play: Biden also planned to raise arms control, bounties allegedly placed on U.S. troops in Afghanistan and the war in Ukraine, according to White House press secretary Jen Psaki, who said the call took place while she was delivering a press briefing. Psaki added that a full readout will be provided later Tuesday.

Go deeper (1 min. read)Arrow

You’ve caught up. Now what?

Sign up for Mike Allen’s daily Axios AM and PM newsletters to get smarter, faster on the news that matters.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!